Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight <https://www.law360.com/competition/articles/2322934?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-09&read_main=1&nlsidx=0&nlaidx=0> By Rae Ann Varona Jazz Pharmaceuticals has agreed to pay $145 million to resolve antitrust litigation accusing it of working with its rival Hikma Pharmaceuticals to stave off generic competitors to Jazz's narcolepsy drug Xyrem, the Ireland-based pharmaceutical company revealed Tuesday. Read full article » <https://www.law360.com/competition/articles/2322934?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-09&read_more=1&nlsidx=0&nlaidx=0> | Save to favorites » <https://www.law360.com/competition/articles/2322934?nl_pk=6e763a2a-9f82-44c1-ad37-dbb872fe3785&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2025-04-09&read_later=1&nlsidx=0&nlaidx=0>